Polycystic Ovary Syndrome
Conditions
Interventions
Experimental Group:Acupoint Catgut Embedding, Metformin, and Health Managemen
Control Group:Metformin, and Health Management
Sponsors
Beijing Luhe Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Patients meeting the diagnostic criteria for PCOS; (2) Meeting the diagnostic criteria for overweight or obesity; (3) Aged between 18 and 40 years; (4) Patients who provided informed consent, voluntarily participated in this study, and were available for follow-up observations.
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with organic diseases such as congenital gonadal dysplasia, structural abnormalities of the reproductive tract, malignant tumors of the reproductive organs, or pituitary tumors; (2) Patients with contraindications or hypersensitivity to metformin; (3) Patients with other diseases, such as Cushing's syndrome, adrenal cortical hyperplasia, androgen-secreting tumors of the adrenal gland or ovary, or thyroid and other endocrine dysfunctions; (4) Patients with severe primary diseases involving the cardiovascular and cerebrovascular systems, liver, kidney, or hematopoietic system, those with keloid constitution, and those with mental disorders; (5) Patients currently participating in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biphasic BBT Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index;TCM Syndrome Score;Female Sex Hormone;Glucose and Lipid Metabolism Indicators;Scores on the Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), 36-Item Short Form Health Survey (SF-36), and the Polycystic Ovary Syndrome Quality of Life Questionnaire (PCOSQ);Untargeted Metabolomics Analysis; | — |
Countries
China
Contacts
Public ContactLiuRui
Beijing Luhe Hospital, Capital Medical University
Outcome results
None listed